Neumora Therapeutics, INC 8-K filings

Neumora Therapeutics announced second quarter 2026 financial results, detailing pipeline advancements, a leadership transition with Joshua Pinto appointed CEO, and a cash runway extending into Q3 2027.

Neumora Therapeutics announced favorable pre-clinical toxicology results for its obesity and cardiometabolic disease drug candidate, NMRA-215, with plans for clinical advancement.

Neumora Therapeutics announced the discontinuation of its navacaprant development program after Phase 3 studies failed to meet primary endpoints, while advancing other pipeline candidates.

Neumora Therapeutics stockholders re-elected three directors and ratified the appointment of Ernst & Young LLP as auditors.

Neumora Therapeutics reported Q1 2026 financial results, highlighting strong cash position and progress across key clinical programs, with several data readouts expected in H2 2026.

Neumora reported Q4 and full-year 2025 results, highlighted new NMRA-511 Alzheimer’s agitation data, full enrollment of KOASTAL-2/-3 with Q2 2026 readouts, selected NMRA-898 for schizophrenia, and pushed NMRA-215 to Q1 2027 amid rat tox retest.

Neumora Therapeutics presents positive Phase 1b data for NMRA-511, demonstrating strong efficacy and favorable tolerability in Alzheimer's disease agitation, particularly in patients with elevated anxiety.

Neumora Therapeutics unveils a robust pipeline update, highlighting promising clinical progress and strategic milestones across its metabolic, neurogenerative, and neuropsychiatric franchises, supported by a cash runway into Q3 2027.

Neumora Therapeutics announced positive Phase 1b results for NMRA-511 in Alzheimer's disease agitation and detailed key pipeline updates and anticipated milestones for 2026.

Neumora Therapeutics, Inc. issued 2.85 million common shares to K2 HealthVentures Equity Trust LLC by converting $2.5 million of a term loan at $0.8774 per share.

Neumora Therapeutics announced its third quarter 2025 financial results, highlighting pipeline progress including class-leading preclinical data for NMRA-215 and a strengthened financial position.

Neumora Therapeutics announced the initiation of a Phase 1 clinical study for NMRA-898, its second M4 positive allosteric modulator for neuropsychiatric disorders.

Neumora Therapeutics announced positive preclinical data for NMRA-215, demonstrating significant weight loss in diet-induced obesity mouse studies, both as monotherapy and in combination with semaglutide.

Neumora Therapeutics announced its second quarter 2025 financial results and provided key updates on its clinical pipeline, including prioritizing obesity for NMRA-215 and anticipating multiple data readouts.

Neumora Therapeutics, Inc. announced that its stockholders approved all four proposals at its Annual Meeting, including the election of two Class II directors, ratification of its auditor, repricing of stock options, and a reverse stock split.

Neumora Therapeutics received a notice from Nasdaq for non-compliance with the minimum bid price requirement, potentially leading to delisting.

Neumora Therapeutics announces its Q1 2025 financial results, provides a business update, and secures a $125 million venture debt facility.

Neumora Therapeutics updates the terms of its stock option repricing plan, setting the closing price for repriced options to the date of the 2025 annual stockholder meeting.

Neumora Therapeutics announced its Q4 and full year 2024 financial results, highlighting progress in clinical trials and a strong cash position to support operations into mid-2026.

Neumora Therapeutics announces the departure of Henry Gosebruch as President and CEO, with Paul L. Berns stepping in as Chairman and CEO, accompanied by new separation and employment agreements.

Neumora Therapeutics announces a leadership transition with Paul L. Berns stepping in as CEO and Joshua Pinto becoming President, effective February 14, 2025.

Neumora Therapeutics presented a corporate update at the J.P. Morgan Healthcare Conference, highlighting its pipeline and clinical development plans.

Neumora Therapeutics' Phase 3 KOASTAL-1 study of navacaprant for major depressive disorder did not achieve statistical significance on its primary endpoint, though it showed an efficacy signal in female participants.

Neumora Therapeutics reported its third quarter 2024 financial results, highlighted by a strong cash position and progress across its clinical pipeline, including upcoming Phase 3 data for its lead drug candidate.

Neumora Therapeutics reported its second quarter 2024 financial results, highlighted by a strong cash position and progress in its clinical pipeline, including upcoming Phase 3 data for its lead drug candidate.

Neumora Therapeutics held its annual meeting on June 13, 2024, where stockholders elected two Class I directors and ratified the selection of Ernst & Young LLP as the company's independent auditor for the fiscal year ending December 31, 2024.

Neumora Therapeutics announced its first quarter 2024 financial results, highlighted by a strong cash position and progress in its clinical programs, including the anticipated Phase 3 data readout for navacaprant in Major Depressive Disorder (MDD).

Neumora Therapeutics' Phase 1 trial of NMRA-266 has been placed on clinical hold by the FDA due to pre-clinical data showing convulsions in rabbits.

Neumora Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting a strong cash position and progress in its clinical programs.